NASDAQ:VCYT Veracyte Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Veracyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $19.97 +0.14 (+0.71%) (As of 06/29/2022 12:00 AM ET) Add Compare Share Today's Range$19.20▼$20.1950-Day Range$15.45▼$23.3252-Week Range$14.85▼$54.13Volume887,180 shsAverage Volume958,105 shsMarket Capitalization$1.43 billionP/E RatioN/ADividend YieldN/APrice Target$42.14 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive VCYT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Veracyte and its competitors with MarketBeat's FREE daily newsletter. Email Address VCYT Stock Forecast (MarketRank)Overall MarketRank™2.12 out of 5 starsMedical Sector475th out of 1,432 stocksMedical Laboratories Industry14th out of 32 stocksAnalyst Opinion: 3.4Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 - 3.4 Analyst's Opinion Consensus RatingVeracyte has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 6 buy ratings, no hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $42.14, Veracyte has a forecasted upside of 111.0% from its current price of $19.97.Amount of Analyst CoverageVeracyte has received no research coverage in the past 90 days. Previous Next 4.9 Community Rank Outperform VotesVeracyte has received 414 “outperform” votes. (Add your “outperform” vote.)Underperform VotesVeracyte has received 141 “underperform” votes. (Add your “underperform” vote.)Community SentimentVeracyte has received 74.59% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Veracyte and other stocks. Vote “Outperform” if you believe VCYT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe VCYT will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldVeracyte does not currently pay a dividend.Dividend GrowthVeracyte does not have a long track record of dividend growth. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Veracyte insiders have bought 590.61% more of their company's stock than they have sold. Specifically, they have bought $979,800.00 in company stock and sold $141,874.00 in company stock.Percentage Held by InsidersOnly 2.90% of the stock of Veracyte is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Veracyte are expected to grow in the coming year, from ($0.86) to ($0.57) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Veracyte is -29.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Veracyte is -29.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVeracyte has a P/B Ratio of 1.29. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Veracyte (NASDAQ:VCYT)Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Genomic Sequencing Classifier and Percepta Nasal Swab Test for lung cancer diagnosis; Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis; and Immunoscore Colon Cancer test for colon cancer diagnosis. It is also developing Percepta Genomic Atlas to help inform lung cancer treatment decisions; Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. Veracyte, Inc. has technology licensing and collaboration arrangements with Johnson & Johnson; Acerta Pharma; and CareDx. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.Read More VCYT Stock News HeadlinesJune 29, 2022 | americanbankingnews.comVeracyte (NASDAQ:VCYT) Shares Down 5.1% June 28, 2022 | businesswire.comVeracyte Named a San Francisco “Bay Area Top Workplace” For Ninth Consecutive Year - Business WireJune 27, 2022 | finance.yahoo.comVeracyte Named a San Francisco "Bay Area Top Workplace" For Ninth Consecutive YearJune 24, 2022 | americanbankingnews.comVeracyte (NASDAQ:VCYT) Trading 7.2% Higher June 20, 2022 | businesswire.comNew Data Show Strong Performance of Veracyte's Afirma GSC in Real-World Clinical Practice - Business WireJune 20, 2022 | finance.yahoo.comNew Data Show Strong Performance of Veracyte’s Afirma GSC in Real-World Clinical PracticeJune 20, 2022 | americanbankingnews.comVeracyte, Inc. (NASDAQ:VCYT) Receives Average Rating of "Buy" from AnalystsJune 18, 2022 | americanbankingnews.comVeracyte (NASDAQ:VCYT) Shares Gap Down on Insider SellingJune 17, 2022 | americanbankingnews.comVeracyte (NASDAQ:VCYT) Shares Up 6.8%June 15, 2022 | finance.yahoo.comInsider Buying: The Veracyte, Inc. (NASDAQ:VCYT) CEO & Director Just Bought 60% More SharesJune 14, 2022 | americanbankingnews.comVeracyte, Inc. (NASDAQ:VCYT) CEO Marc Stapley Buys 60,000 SharesJune 12, 2022 | americanbankingnews.comVeracyte (NASDAQ:VCYT) Trading Down 5.8%June 5, 2022 | americanbankingnews.comVeracyte (NASDAQ:VCYT) Shares Gap Down to $18.23See More Headlines Industry, Sector and Symbol Stock ExchangeNASDAQ Industry Medical laboratories Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VCYT CUSIPN/A CIK1384101 Webwww.veracyte.com Phone(650) 243-6300Fax650-243-6301Employees761Year FoundedN/ACompany Calendar Last Earnings5/03/2022Today6/30/2022Next Earnings (Estimated)8/04/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$42.14 High Stock Price Forecast$59.00 Low Stock Price Forecast$26.00 Forecasted Upside/Downside+111.0%Consensus RatingModerate Buy Rating Score (0-4)2.71428571428571 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($0.680010) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-75.56 million Net Margins-19.22% Pretax Margin-20.13% Return on Equity-4.09% Return on Assets-3.81% Debt Debt-to-Equity RatioN/A Current Ratio3.81 Quick Ratio3.62 Sales & Book Value Annual Sales$219.51 million Price / Sales6.50 Cash FlowN/A Price / Cash FlowN/A Book Value$15.43 per share Price / Book1.29Miscellaneous Outstanding Shares71,445,000Free Float69,373,000Market Cap$1.43 billion OptionableOptionable Beta1.12 Veracyte Frequently Asked Questions Should I buy or sell Veracyte stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Veracyte in the last twelve months. There are currently 1 sell rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" Veracyte stock. View analyst ratings for Veracyte or view top-rated stocks. What is Veracyte's stock price forecast for 2022? 7 brokers have issued 1 year target prices for Veracyte's stock. Their VCYT stock forecasts range from $26.00 to $59.00. On average, they expect Veracyte's share price to reach $42.14 in the next twelve months. This suggests a possible upside of 111.0% from the stock's current price. View analysts' price targets for Veracyte or view top-rated stocks among Wall Street analysts. How has Veracyte's stock price performed in 2022? Veracyte's stock was trading at $41.20 at the beginning of 2022. Since then, VCYT shares have decreased by 51.5% and is now trading at $19.97. View the best growth stocks for 2022 here. When is Veracyte's next earnings date? Veracyte is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast for Veracyte. How were Veracyte's earnings last quarter? Veracyte, Inc. (NASDAQ:VCYT) released its quarterly earnings results on Tuesday, May, 3rd. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.23) by $0.03. The biotechnology company earned $67.78 million during the quarter, compared to analyst estimates of $61.98 million. Veracyte had a negative trailing twelve-month return on equity of 4.09% and a negative net margin of 19.22%. During the same quarter in the previous year, the business posted ($0.11) earnings per share. View Veracyte's earnings history. What guidance has Veracyte issued on next quarter's earnings? Veracyte issued an update on its FY 2022 earnings guidance on Monday, May, 9th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $265.00 million-$275.00 million, compared to the consensus revenue estimate of $270.30 million. Who are Veracyte's key executives? Veracyte's management team includes the following people: Ms. Bonnie H. Anderson, Co-Founder & Exec. Chairwoman (Age 64, Pay $1.21M) (LinkedIn Profile)Mr. Marc A. Stapley, CEO & Director (Age 52, Pay $900.4k)Ms. Rebecca Chambers, Exec. VP & CFO (Age 44, Pay $607.65k)Dr. Giulia C. Kennedy Ph.D., Global Chief Scientific Officer & Chief Medical Officer (Age 63, Pay $691.33k)Dr. Tina S. Nova Ph.D., Pres of CLIA U.S. Bus. (Age 68, Pay $4.58k)Ms. Beverly Jane Alley CPA, VP & Corp. Controller (Age 59, Pay $398.01k)Mr. Jonathan Wygant, VP & Chief Accounting Officer (Age 51)Mr. William W. Zondler, Sr. VP & Chief Information OfficerMs. Annie McGuire, Sr. VP & Gen. Counsel (Age 42)Ms. Tracy Morris, VP of Global Corp. Communications Who are some of Veracyte's key competitors? Some companies that are related to Veracyte include Guardant Health (GH), Natera (NTRA), Elekta AB (publ) (EKTAY), Fulgent Genetics (FLGT), CareDx (CDNA), RadNet (RDNT), Castle Biosciences (CSTL), Invitae (NVTA), Viridian Therapeutics (VRDN), Burning Rock Biotech (BNR), DermTech (DMTK), Personalis (PSNL), Renalytix (RNLX), Genetron (GTH) and Progenity (PROG). View all of VCYT's competitors. What other stocks do shareholders of Veracyte own? Based on aggregate information from My MarketBeat watchlists, some companies that other Veracyte investors own include Hawkins (HWKN), Invitae (NVTA), AbbVie (ABBV), CA (CA), CRISPR Therapeutics (CRSP), Advanced Micro Devices (AMD), Editas Medicine (EDIT), NVIDIA (NVDA), Exelixis (EXEL) and NeoGenomics (NEO). What is Veracyte's stock symbol? Veracyte trades on the NASDAQ under the ticker symbol "VCYT." How do I buy shares of Veracyte? Shares of VCYT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Veracyte's stock price today? One share of VCYT stock can currently be purchased for approximately $19.97. How much money does Veracyte make? Veracyte (NASDAQ:VCYT) has a market capitalization of $1.43 billion and generates $219.51 million in revenue each year. The biotechnology company earns $-75.56 million in net income (profit) each year or ($0.680010) on an earnings per share basis. How many employees does Veracyte have? Veracyte employs 761 workers across the globe. How can I contact Veracyte? Veracyte's mailing address is 6000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The official website for Veracyte is www.veracyte.com. The biotechnology company can be reached via phone at (650) 243-6300, via email at [email protected], or via fax at 650-243-6301. This page (NASDAQ:VCYT) was last updated on 6/30/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here